First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical …

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave BioPharma; Jack Syage, Ph.D., named President and Chief Operating Officer A strategic U.S. commercial license…#jamessapirstein #firstwavebiopharma #jacksyage #phd #bocaraton #fla #biopharmainc #fwbi #chaitankhosla #firstwave
Source: Reuters: Health - Category: Consumer Health News Source Type: news